O. Petrenciuc

发表

Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer

M. Piccart, C. Takimoto, M. Moore, 2006, Clinical Cancer Research.

A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel

D. Elder, K. Flaherty, B. Weber, 2008, Clinical Cancer Research.

Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignancies

A. Oza, L. Seymour, W. Miller, 2005, Investigational New Drugs.

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.

F. Saad, J. Carles, M. Wirth, 2016, The Lancet. Oncology.

Sorafenib combined with carboplatin/paclitaxel for advanced non-small cell lung cancer: A phase I subset analysis.

K. Flaherty, J. Schiller, P. O'dwyer, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ra-223 experience in pretreated patients: EAP setting.

A. Iagaru, M. Morris, A. Dicker, 2015 .

A phase I/II trial of BAY 43-9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer.

M. Piccart, C. Takimoto, M. Moore, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of BAY 43–9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC)

G. Pond, L. Siu, O. Petrenciuc, 2005 .

Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial.

S. Fosså, C. Parker, N. James, 2017, European urology.

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.

T. Tammela, A. Snapir, O. Petrenciuc, 2020, The New England journal of medicine.

Chemotherapy following radium‐223 dichloride treatment in ALSYMPCA

C. Parker, P. Hoskin, S. Nilsson, 2016, The Prostate.

Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial

T. Tammela, B. Ploeger, O. Petrenciuc, 2019, Targeted Oncology.

Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.

G. Pond, L. Siu, J. Elting, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC).

T. Tammela, A. Snapir, O. Petrenciuc, 2020 .

Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial

M. Morris, E. Antonarakis, C. Higano, 2019, European journal of cancer.

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

A. Oza, H. Hirte, L. Siu, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program.

A. Iagaru, M. Morris, A. Dicker, 2018, The oncologist.

A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial

C. Hudis, W. Gradishar, J. Baselga, 2013, Trials.

2530 Baseline characteristics, number of radium-223 (Ra-223) injections, and overall survival (OS) in US Expanded Access Program (EAP) and ALSYMPCA

C. Parker, M. Morris, S. Nilsson, 2015 .

A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma.

A. Oza, I. Ray-Coquard, Byoung-Gie Kim, 2013, Gynecologic oncology.

Abstract OT1-04-05: A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2-negative, hormone receptor–positive breast cancer and bone metastases

H. Rugo, M. Campone, O. Petrenciuc, 2017 .

A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2–negative hormone receptor–positive breast cancer and bone metastases

H. Rugo, O. Petrenciuc, R. Coleman, 2016 .

Radium-223 dichloride (Ra-223) in U.S. expanded access program (EAP).

A. Iagaru, M. Morris, A. Dicker, 2015 .

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.

F. Saad, J. Carles, M. Wirth, 2016, The Lancet. Oncology.

Design of RESILIENCE: A phase (Ph) III trial comparing capecitabine (CAP) in combination with sorafenib (SOR) or placebo (PL) for treatment (tx) of locally advanced (adv) or metastatic HER2-negative breast cancer (BC).

J. Baselga, O. Petrenciuc, M. Shan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.